Skip to Content

CALGB C80702, A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Objective
This is a clinical trial of celecoxib that will be administered by mouth which is investigational and "FOLFOX"; a combination of 5-flourouracil (also called 5-FU), leucovorin and oxaliplatin that will be administered by IV and is standard of care.
IRB Protocol Number
10-1455
Principal Investigator(s)
STEPHEN LEONG

Cancer Trials

  • Digestive System Cancer
Sponsor(s)
CALGB
Contact
KIRSTEN MILLER at 720-848-5278
or KIRSTEN.MILLER@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 3 years.. A follow up period will consist of phone contact or clinic visit. // Eligibility criteria include but are not limited to 18 years or older with colon cancer that has spread to lymph nodes.

Location

  • Alamosa
  • Dept Of Veterans Affairs Medical Center
  • Montrose Memorial Hospital
  • Shaw Regional Cancer Center (Vail)
  • ST. MARYS HOSPITAL - G.J.
  • Valley View Hospital